β1-adrenergic receptor activation enhances memory in Alzheimer's disease model

Annals of Clinical and Translational Neurology

Volumn 1, Issue 5, 2014, Pages 348-360

  Coutellier, Laurence ^a   Ardestani, Pooneh Memar ^a   Shamloo, Mehrdad ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETAXOLOL; CYCLIC AMP DEPENDENT PROTEIN KINASE; XAMOTEROL;

ADULT; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; COGNITION; COGNITIVE DEFECT; DOWNSTREAM PROCESSING; IMMUNOHISTOCHEMISTRY; MEDIAL AMYGDALA; MOUSE; NONHUMAN; OLFACTORY DISCRIMINATION; PRIORITY JOURNAL; SOCIAL RECOGNITION TEST;

EID: 85009846423     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.57     Document Type: Article

References (43)

1. Werheid K, Clare L. Are faces special in Alzheimer's disease? Cognitive conceptualisation, neural correlates, and diagnostic relevance of impaired memory for faces and names. Cortex 2007;43:898–906.
2. Wilson RS, Kaszniak AW, Bacon LD, et al. Facial recognition memory in dementia. Cortex 1982;18:329–336.
3. Bielsky IF, Hu SB, Szegda KL, et al. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 2004;29:483–493.
4. Young LJ. The neurobiology of social recognition, approach, and avoidance. Biol Psychiatry 2002;51:18–26.
5. Higashida H, Yokoyama S, Huang JJ, et al. Social memory, amnesia, and autism: brain oxytocin secretion is regulated by NAD+ metabolites and single nucleotide polymorphisms of CD38. Neurochem Int 2012;61:828–838.
6. Meynen G, Unmehopa UA, Hofman MA, et al. Hypothalamic vasopressin and oxytocin mRNA expression in relation to depressive state in Alzheimer's disease: a difference with major depressive disorder. J Neuroendocrinol 2009;21:722–729.
7. Mazurek MF, Beal MF, Bird ED, Martin JB. Oxytocin in Alzheimer's disease: postmortem brain levels. Neurology 1987;37:1001–1003.
8. Bondareff W, Mountjoy CQ, Roth M, et al. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord 1987;1:256–262.
9. Tomlinson BE, Irving D, Blessed G. Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J Neurol Sci 1981;49:419–428.
10. Gibbs ME, Summers RJ. Role of adrenoceptor subtypes in memory consolidation. Prog Neurobiol 2002;67:345–391.
11. Madison DV, Nicoll RA. Norepinephrine decreases synaptic inhibition in the rat hippocampus. Brain Res 1988;442:131–138.
12. Murchison CF, Zhang XY, Zhang WP, et al. A distinct role for norepinephrine in memory retrieval. Cell 2004;117:131–143.
13. Kleschevnikov AM, Belichenko PV, Salehi A, Wu C. Discoveries in Down syndrome: moving basic science to clinical care. Prog Brain Res 2012;197:199–221.
14. Faizi M, Bader PL, Tun C, et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis 2011;43:397–413.
15. Salehi A, Faizi M, Colas D, et al. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med 2009;1:7ra17.
16. Bullido MJ, Ramos MC, Ruiz-Gomez A, et al. Polymorphism in genes involved in adrenergic signaling associated with Alzheimer's. Neurobiol Aging 2004;25:853–859.
17. Marino MD, Bourdelat-Parks BN, Cameron Liles L, Weinshenker D. Genetic reduction of noradrenergic function alters social memory and reduces aggression in mice. Behav Brain Res 2005;161:197–203.
18. Heneka MT, Ramanathan M, Jacobs AH, et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 2006;26:1343–1354.
19. Rockenstein E, Mallory M, Mante M, et al. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J Neurosci Res 2001;66:573–582.
20. Faizi M, Bader PL, Saw N, et al. Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav 2012;2:142–154.
21. Nadler JJ, Moy SS, Dold G, et al. Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain Behav 2004;3:303–314.
22. Macbeth AH, Edds JS, Young WS III. Housing conditions and stimulus females: a robust social discrimination task for studying male rodent social recognition. Nat Protoc 2009;4:1574–1581.
23. Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates. Compact 2nd ed. Amsterdam, Boston: Elsevier Academic Press, 2004.
24. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991;231:482–497.
25. Gundersen HJ, Jensen EB, Kieu K, Nielsen J. The efficiency of systematic sampling in stereology–reconsidered. J Microsc 1999;193:199–211.
26. Borelli KG, Blanchard DC, Javier LK, et al. Neural correlates of scent marking behavior in C57BL/6J mice: detection and recognition of a social stimulus. Neuroscience 2009;162:914–923.
27. Ferguson JN, Aldag JM, Insel TR, Young LJ. Oxytocin in the medial amygdala is essential for social recognition in the mouse. J Neurosci 2001;21:8278–8285.
28. Chu CT, Plowey ED, Wang Y, et al. Location, location, location: altered transcription factor trafficking in neurodegeneration. J Neuropathol Exp Neurol 2007;66:873–883.
29. Chung SH. Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. BMB Rep 2009;42:467–474.
30. Ke YD, Dramiga J, Schutz U, et al. Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease. PLoS One 2012;7:e35678.
31. Brennan P, Kaba H, Keverne EB. Olfactory recognition: a simple memory system. Science 1990;250:1223–1226.
32. Dluzen DE, Muraoka S, Landgraf R. Olfactory bulb norepinephrine depletion abolishes vasopressin and oxytocin preservation of social recognition responses in rats. Neurosci Lett 1998;254:161–164.
33. Sara SJ, Vankov A, Herve A. Locus coeruleus-evoked responses in behaving rats: a clue to the role of noradrenaline in memory. Brain Res Bull 1994;35:457–465.
34. Rasia-Filho AA, Londero RG, Achaval M. Functional activities of the amygdala: an overview. J Psychiatry Neurosci 2000;25:14–23.
35. Kromer Vogt LJ, Hyman BT, Van Hoesen GW, Damasio AR. Pathological alterations in the amygdala in Alzheimer's disease. Neuroscience 1990;37:377–385.
36. Unger JW, Lapham LW, McNeill TH, et al. The amygdala in Alzheimer's disease: neuropathology and Alz 50 immunoreactivity. Neurobiol Aging 1991;12:389–399.
37. Morrone I, Besche-Richard C, Mahmoudi R, Novella JL. Identification and memorisation of emotions in Alzheimer's disease: a critical review of litterature. Geriatr Psychol Neuropsychiatr Vieil 2012;10:307–314.
38. Grady CL, Furey ML, Pietrini P, et al. Altered brain functional connectivity and impaired short-term memory in Alzheimer's disease. Brain 2001;124:739–756.
39. De Luca A, Giuditta A. Role of a transcription factor (CREB) in memory processes. Riv Biol 1997;90:371–384.
40. Izquierdo LA, Barros DM, Vianna MR, et al. Molecular pharmacological dissection of short- and long-term memory. Cell Mol Neurobiol 2002;22:269–287.
41. Suzuki A, Fukushima H, Mukawa T, et al. Upregulation of CREB-mediated transcription enhances both short- and long-term memory. J Neurosci 2011;31:8786–8802.
42. Arvanitis DN, Ducatenzeiler A, Ou JN, et al. High intracellular concentrations of amyloid-beta block nuclear translocation of phosphorylated CREB. J Neurochem 2007;103:216–228.
43. Windisch M, Flunkert S, Havas D, Hutter-Paier B. Commentary to the recently published review “Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease” by Li, Evrahimi and Schluesener Ageing Res. Rev. 2013;12(1):116-40. Ageing Res Rev 2013;12:852–854.